Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15946336 | 0.86 | ACHE (0.50) | NPC1RAB9ASMN1; SMN2ACHEBCHE | |
| SCHEMBL16729242 | 0.78 | NPC1 (0.52) | TP53NPC1RAB9AKDM4EGLA | |
| SCHEMBL10062380 | 0.70 | KDM5A (0.70) | MAPTACHEBCHEHTT | |
| SCHEMBL16496746 | 0.65 | RAB9A (1.00) | TP53NPC1RAB9AKDM4EGLA | |
| SCHEMBL9926442 | 0.63 | BCHE (1.00) | NPC1MAPTACHEBCHE | |
| SCHEMBL3798774 | 0.61 | HTT (0.55) | MAPTACHEBCHEHTT | |
| SCHEMBL6705932 | 0.61 | NPC1 (0.61) | TP53NPC1RAB9AKDM4EGLA | |
| SCHEMBL18974033 | 0.59 | KDM4E (0.55) | TP53NPC1RAB9AKDM4EMAPT | |
| SCHEMBL13885354 | 0.59 | ACHE (0.71) | TP53KDM4EMAPTACHEBCHE | |
| SCHEMBL27805412 | 0.59 | RAB9A (0.57) | TP53NPC1RAB9AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | UWM RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2013036749-A1 | HCV HELICASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF KANSAS (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | DHX15, DDX5, DHX35 | TP53 446/4885NPC1 2518/4885RAB9A 3431/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | TP53 1568/4885NPC1 1169/4885RAB9A 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.